Recent Developments of Hematologic Diagnostics in the Interplay with Evolving Treatment Developments

Dear Colleagues,

Hematologic diagnostics underwent a rapid expansion in recent years, mainly due to the introduction of next-generation sequencing (NGS) and improved minimal residual disease (MRD) strategies. At the same time, with the expansion of therapeutic options for hematologic malignancies by kinase inhibitors, monoclonal antibodies, as well as novel immunotherapeutic approaches by CAR-T cells and bispecific antibodies, individualized treatment strategies become increasingly available for patients both at diagnosis or at relapse with myeloid or lymphoproliferative malignancies. This specific issue illustrates the current landscape of diagnostic options for patients with hemato-oncologic malignancies at first manifestation and at follow-up, and it provides insights into the interaction of these emerging diagnostic possibilities together with established and novel therapeutic options. Future perspectives for further optimizing this interplay between diagnostics and therapeutic options are discussed.

Prof. Dr. Ulrike Bacher
Prof. Dr. Thomas Pabst
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.